Top

Published in:

01-01-2020 | NSCLC | Review

mTOR in Lung Neoplasms

Authors: Ildiko Krencz, Anna Sebestyen, Andras Khoor

Published in: Pathology & Oncology Research | Issue 1/2020

Abstract

With the discovery of rapamycin 45 years ago, studies in the mechanistic target of rapamycin (mTOR) field started 2 decades before the identification of the mTOR kinase. Over the years, studies revealed that the mTOR signaling is a master regulator of homeostasis and integrates a variety of environmental signals to regulate cell growth, proliferation, and metabolism. Deregulation of mTOR signaling, particularly hyperactivation, frequently occurs in human tumors. Recent advances in molecular profiling have identified mutations or amplification of certain genes coding proteins involved in the mTOR pathway (eg, PIK3CA, PTEN, STK11, and RICTOR) as the most common reasons contributing to mTOR hyperactivation. These genetic alterations of the mTOR pathway are frequently observed in lung neoplasms and may serve as a target for personalized therapy. mTOR inhibitor monotherapy has met limited clinical success so far; however, rational drug combinations are promising to improve efficacy and overcome acquired resistance. A better understanding of mTOR signaling may have the potential to help translation of mTOR pathway inhibitors into the clinical setting.

Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28(10):721–726. https://doi.org/10.7164/antibiotics.28.721 CrossRef

Eng CP, Sehgal SN, Vezina C (1984) Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37(10):1231–1237. https://doi.org/10.7164/antibiotics.37.1231 CrossRef

Martel RR, Klicius J, Galet S (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55(1):48–51. https://doi.org/10.1139/y77-007 CrossRefPubMed

Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78(1):35–43. https://doi.org/10.1016/0092-8674(94)90570-3 CrossRefPubMed

Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT (1995) Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815–822. https://doi.org/10.1074/jbc.270.2.815 CrossRefPubMed

Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293. https://doi.org/10.1016/j.cell.2012.03.017 CrossRefPubMedPubMedCentral

Gkountakos A, Pilotto S, Mafficini A, Vicentini C, Simbolo M, Milella M, Tortora G, Scarpa A, Bria E, Corbo V (2018) Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis. https://doi.org/10.1093/carcin/bgy086

Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168(6):960–976. https://doi.org/10.1016/j.cell.2017.02.004 CrossRefPubMedPubMedCentral

Shimobayashi M, Hall MN (2014) Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15(3):155–162. https://doi.org/10.1038/nrm3757 CrossRefPubMed

10.

Tian T, Li X, Zhang J (2019) mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 20(3). https://doi.org/10.3390/ijms20030755

11.

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K pathway in human disease. Cell 170(4):605–635. https://doi.org/10.1016/j.cell.2017.07.029 CrossRefPubMedPubMedCentral

12.

Yip CK, Murata K, Walz T, Sabatini DM, Kang SA (2010) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38(5):768–774. https://doi.org/10.1016/j.molcel.2010.05.017 CrossRefPubMedPubMedCentral

13.

Shaw RJ (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 196(1):65–80. https://doi.org/10.1111/j.1748-1716.2009.01972.x CrossRef

14.

Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10(8):935–945. https://doi.org/10.1038/ncb1753 CrossRefPubMedPubMedCentral

15.

Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18(12):744–757. https://doi.org/10.1038/s41568-018-0074-8 CrossRefPubMed

16.

Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16(12):1472–1487. https://doi.org/10.1101/gad.995802 CrossRefPubMedPubMedCentral

17.

Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM (2011) mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146(3):408–420. https://doi.org/10.1016/j.cell.2011.06.034 CrossRefPubMedPubMedCentral

18.

Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8(3):224–236. https://doi.org/10.1016/j.cmet.2008.07.007 CrossRefPubMedPubMedCentral

19.

Ben-Sahra I, Howell JJ, Asara JM, Manning BD (2013) Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339(6125):1323–1328. https://doi.org/10.1126/science.1228792 CrossRefPubMedPubMedCentral

20.

Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD (2016) mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351(6274):728–733. https://doi.org/10.1126/science.aad0489 CrossRefPubMedPubMedCentral

21.

Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132–141. https://doi.org/10.1038/ncb2152 CrossRefPubMedPubMedCentral

22.

Martina JA, Chen Y, Gucek M, Puertollano R (2012) MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy 8(6):903–914. https://doi.org/10.4161/auto.19653 CrossRefPubMedPubMedCentral

23.

Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P (2007) mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450(7170):736–740. https://doi.org/10.1038/nature06322 CrossRefPubMed

24.

Cam H, Easton JB, High A, Houghton PJ (2010) mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell 40(4):509–520. https://doi.org/10.1016/j.molcel.2010.10.030 CrossRefPubMedPubMedCentral

25.

Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR (2015) mTORC1 drives HIF-1alpha and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34(17):2239–2250. https://doi.org/10.1038/onc.2014.164 CrossRefPubMed

26.

Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39(2):171–183. https://doi.org/10.1016/j.molcel.2010.06.022 CrossRefPubMedPubMedCentral

27.

Tsang CK, Chen M, Cheng X, Qi Y, Chen Y, Das I, Li X, Vallat B, Fu LW, Qian CN, Wang HY, White E, Burley SK, Zheng XFS (2018) SOD1 phosphorylation by mTORC1 couples nutrient sensing and redox regulation. Mol Cell 70(3):502–515.e508. https://doi.org/10.1016/j.molcel.2018.03.029 CrossRefPubMedPubMedCentral

28.

Stuttfeld E, Aylett CH, Imseng S, Boehringer D, Scaiola A, Sauer E, Hall MN, Maier T, Ban N (2018) Architecture of the human mTORC2 core complex. Elife 7. https://doi.org/10.7554/eLife.33101

29.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101. https://doi.org/10.1126/science.1106148 CrossRefPubMed

30.

Kazyken D, Magnuson B, Bodur C, Acosta-Jaquez HA, Zhang D, Tong X, Barnes TM, Steinl GK, Patterson NE, Altheim CH, Sharma N, Inoki K, Cartee GD, Bridges D, Yin L, Riddle SM, Fingar DC (2019) AMPK directly activates mTORC2 to promote cell survival during acute energetic stress. Sci Signal 12(585). https://doi.org/10.1126/scisignal.aav3249

31.

Luo Y, Xu W, Li G, Cui W (2018) Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism. Oxid Med Cell Longev 2018:7838647. https://doi.org/10.1155/2018/7838647 CrossRefPubMedPubMedCentral

32.

Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK Sarbassov dos D (2011) ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor. Sci Signal 4(161):ra10. https://doi.org/10.1126/scisignal.2001731

33.

Dibble CC, Asara JM, Manning BD (2009) Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 29(21):5657–5670. https://doi.org/10.1128/mcb.00735-09 CrossRefPubMedPubMedCentral

34.

Koo J, Wu X, Mao Z, Khuri FR, Sun SY (2015) Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. J Biol Chem 290(22):14120–14129. https://doi.org/10.1074/jbc.M114.633057 CrossRefPubMedPubMedCentral

35.

Zinzalla V, Stracka D, Oppliger W, Hall MN (2011) Activation of mTORC2 by association with the ribosome. Cell 144(5):757–768. https://doi.org/10.1016/j.cell.2011.02.014 CrossRefPubMed

36.

Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562. https://doi.org/10.1038/nrc2664 CrossRefPubMed

37.

Fumarola C, Bonelli MA, Petronini PG, Alfieri RR (2014) Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 90(3):197–207. https://doi.org/10.1016/j.bcp.2014.05.011 CrossRefPubMed

38.

Yehia L, Ngeow J, Eng C (2019) PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest 129(2):452–464. https://doi.org/10.1172/jci121277 CrossRefPubMedPubMedCentral

39.

Shorning BY, Griffiths D, Clarke AR (2011) Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One 6(1):e16209. https://doi.org/10.1371/journal.pone.0016209 CrossRefPubMedPubMedCentral

40.

Harris TK (2003) PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design. IUBMB Life 55(3):117–126. https://doi.org/10.1080/1521654031000115951 CrossRefPubMed

41.

Hart JR, Vogt PK (2011) Phosphorylation of AKT: a mutational analysis. Oncotarget 2(6):467–476CrossRef

42.

Arsham AM, Howell JJ, Simon MC (2003) A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 278(32):29655–29660. https://doi.org/10.1074/jbc.M212770200 CrossRefPubMed

43.

Brinkhuizen T, Weijzen CA, Eben J, Thissen MR, van Marion AM, Lohman BG, Winnepenninckx VJ, Nelemans PJ, van Steensel MA (2014) Immunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma. PLoS One 9(9):e106427. https://doi.org/10.1371/journal.pone.0106427 CrossRefPubMedPubMedCentral

44.

Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18(23):2893–2904. https://doi.org/10.1101/gad.1256804 CrossRefPubMedPubMedCentral

45.

Kim J, Guan KL (2019) mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol 21(1):63–71. https://doi.org/10.1038/s41556-018-0205-1 CrossRefPubMed

46.

Roccio M, Bos JL, Zwartkruis FJ (2006) Regulation of the small GTPase Rheb by amino acids. Oncogene 25(5):657–664. https://doi.org/10.1038/sj.onc.1209106 CrossRefPubMed

47.

Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM (2013) A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340(6136):1100–1106. https://doi.org/10.1126/science.1232044 CrossRefPubMedPubMedCentral

48.

Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320(5882):1496–1501. https://doi.org/10.1126/science.1157535 CrossRefPubMedPubMedCentral

49.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R (2015) RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors. Cancer Discov 5(12):1262–1270. https://doi.org/10.1158/2159-8290.Cd-14-0971 CrossRefPubMedPubMedCentral

50.

Janku F, Yap TA, Meric-Bernstam F (2018) Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15(5):273–291. https://doi.org/10.1038/nrclinonc.2018.28 CrossRefPubMed

51.

Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M (2006) Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12(3 Pt 1):710–717. https://doi.org/10.1158/1078-0432.Ccr-05-1362 CrossRefPubMed

52.

Papadimitrakopoulou V (2012) Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 7(8):1315–1326. https://doi.org/10.1097/JTO.0b013e31825493eb CrossRefPubMed

53.

Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4(5):476–495PubMedPubMedCentral

54.

Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W, Cao Y, Zhao S, Zhang W, Qiu Z, Liu D, Mo X, Li W (2015) Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. J Exp Clin Cancer Res 34:126. https://doi.org/10.1186/s13046-015-0239-1 CrossRefPubMedPubMedCentral

55.

Krencz I, Sebestyen A, Fabian K, Mark A, Moldvay J, Khoor A, Kopper L, Papay J (2017) Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. Hum Pathol 62:66–73. https://doi.org/10.1016/j.humpath.2016.12.012 CrossRefPubMed

56.

Seki N, Takasu T, Mandai K, Nakata M, Saeki H, Heike Y, Takata I, Segawa Y, Hanafusa T, Eguchi K (2002) Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 8(10):3046–3053PubMed

57.

Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16(1):240–248. https://doi.org/10.1158/1078-0432.Ccr-09-0986 CrossRefPubMed

58.

Ekman S, Wynes MW, Hirsch FR (2012) The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol 7(6):947–953. https://doi.org/10.1097/JTO.0b013e31825581bd CrossRefPubMed

59.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B (2017) LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Lung Cancer 112:62–68. https://doi.org/10.1016/j.lungcan.2017.08.002 CrossRefPubMed

60.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR (2012) Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 18(24):6771–6783. https://doi.org/10.1158/1078-0432.Ccr-12-2347 CrossRefPubMed

61.

Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansen S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Janne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107–1120CrossRef

62.

Vasan N, Boyer JL, Herbst RS (2014) A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res 20(15):3921–3930CrossRef

63.

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart. International Agency for Research on Cancer, Lyon

64.

Gazdar AF, Bunn PA, Minna JD (2017) Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 17(12):725–737. https://doi.org/10.1038/nrc.2017.87 CrossRefPubMed

65.

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H, Ishii G, Udagawa H, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Aokage K, Hishida T, Yoshida J, Nagai K, Goto K, Tsuboi M, Tsuchihara K (2017) Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res 23(3):757–765. https://doi.org/10.1158/1078-0432.Ccr-16-0355 CrossRefPubMed

66.

Simbolo M, Mafficini A, Sikora KO, Fassan M, Barbi S, Corbo V, Mastracci L, Rusev B, Grillo F, Vicentini C, Ferrara R, Pilotto S, Davini F, Pelosi G, Lawlor RT, Chilosi M, Tortora G, Bria E, Fontanini G, Volante M, Scarpa A (2017) Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J Pathol 241(4):488–500CrossRef

67.

Hendifar AE, Marchevsky AM, Tuli R (2017) Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol 12(3):425–436. https://doi.org/10.1016/j.jtho.2016.11.2222 CrossRefPubMed

68.

George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Muller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Putzer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmuller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castanos-Velez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Kohler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansen S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nurnberg P, Reinhardt C, Perner S, Heukamp L, Buttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524(7563):47–53CrossRef

69.

Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44(10):1111–1116. https://doi.org/10.1038/ng.2405 CrossRefPubMedPubMedCentral

70.

Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, Niho S, Yoh K, Matsumoto S, Takahashi A, Morise M, Nakamura Y, Ochiai A, Nagai K, Iwakawa R, Kohno T, Yokota J, Ohe Y, Esumi H, Tsuchihara K, Goto K (2014) Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 9(9):1324–1331CrossRef

71.

Krencz I, Sebestyen A, Papay J, Lou Y, Lutz GF, Majewicz TL, Khoor A (2019) Correlation between immunohistochemistry and RICTOR FISH amplification in small cell lung carcinoma. Hum Pathol. https://doi.org/10.1016/j.humpath.2019.08.018

72.

Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, Stephens PJ (2014) Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67(9):772–776CrossRef

73.

Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A (2017) RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. Oncotarget 8(4):5992–6002CrossRef

74.

Schmid K, Bago-Horvath Z, Berger W, Haitel A, Cejka D, Werzowa J, Filipits M, Herberger B, Hayden H, Sieghart W (2010) Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103(5):622–628. https://doi.org/10.1038/sj.bjc.6605761 CrossRefPubMedPubMedCentral

75.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 10(9):1243–1260. https://doi.org/10.1097/jto.0000000000000630 CrossRefPubMed

76.

Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, Moses M, Darling T, Moss J (2010) Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 104(Suppl 1):S45–S58CrossRef

77.

Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest 122(11):3807–3816CrossRef

78.

Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62(4):810–815CrossRef

79.

Badri KR, Gao L, Hyjek E, Schuger N, Schuger L, Qin W, Chekaluk Y, Kwiatkowski DJ, Zhe X (2013) Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 187(6):663–665. https://doi.org/10.1164/ajrccm.187.6.663 CrossRefPubMedPubMedCentral

80.

Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97(11):6085–6090. https://doi.org/10.1073/pnas.97.11.6085 CrossRefPubMedPubMedCentral

81.

Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47(1):20–28. https://doi.org/10.1007/s10038-002-8651-8 CrossRefPubMed

82.

Adachi K, Miki Y, Saito R, Hata S, Yamauchi M, Mikami Y, Okada Y, Seyama K, Kondo T, Sasano H (2015) Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis. Hum Pathol 46(11):1685–1693. https://doi.org/10.1016/j.humpath.2015.02.019 CrossRefPubMed

83.

Hayashi T, Kumasaka T, Mitani K, Okada Y, Kondo T, Date H, Chen F, Oto T, Miyoshi S, Shiraishi T, Iwasaki A, Hara K, Saito T, Ando K, Kobayashi E, Gunji-Niitsu Y, Kunogi M, Takahashi K, Yao T, Seyama K (2016) Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol 50:34–42. https://doi.org/10.1016/j.humpath.2015.11.002 CrossRefPubMed

84.

Krencz I, Sebestyen A, Papay J, Jeney A, Hujber Z, Burger CD, Keller CA, Khoor A (2018) In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human lymphangioleiomyomatosis. Hum Pathol 79:199–207. https://doi.org/10.1016/j.humpath.2018.05.018 CrossRefPubMed

85.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J (2016) Official american thoracic society/Japanese respiratory society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med 194(6):748–761CrossRef

86.

Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M (2018) mTOR cross-talk in cancer and potential for combination therapy. Cancers (Basel) 10(1). https://doi.org/10.3390/cancers10010023

87.

Zheng Y, Jiang Y (2015) mTOR inhibitors at a glance. Mol Cell Pharmacol 7(2):15–20PubMedPubMedCentral

88.

Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20(10):1674–1681. https://doi.org/10.1093/annonc/mdp060 CrossRefPubMed

89.

Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM (2013) Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled radiant-2 study. Chest 143(4):955–962. https://doi.org/10.1378/chest.12-1108 CrossRefPubMed

90.

Pavel ME, Baudin E, Oberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC (2017) Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Ann Oncol 28(7):1569–1575. https://doi.org/10.1093/annonc/mdx193 CrossRefPubMed

91.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977. https://doi.org/10.1016/s0140-6736(15)00817-x CrossRefPubMed

92.

Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Lena H, Berruti A, Damiano V, Buikhuisen W, Gronbaek H, Lombard-Bohas C, Grohe C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Oberg K, Baudin E (2017) Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 18(12):1652–1664. https://doi.org/10.1016/s1470-2045(17)30681-2 CrossRefPubMed

93.

Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH (2007) A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2(11):1036–1041. https://doi.org/10.1097/JTO.0b013e318155a439 CrossRefPubMed

94.

Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A (2010) Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16(23):5900–5907. https://doi.org/10.1158/1078-0432.Ccr-10-0802 CrossRefPubMed

95.

Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, Doi T, Iwakami S, Takahashi K, Seyama K, Mikami M (2013) Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 51(3):175–183. https://doi.org/10.1016/j.resinv.2013.03.002 CrossRefPubMed

96.

Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP (2015) Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J 46(3):783–794. https://doi.org/10.1183/09031936.00210714 CrossRefPubMed

97.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364(17):1595–1606CrossRef

98.

Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J (2014) Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 190(11):1273–1282CrossRef

99.

Xu KF, Tian X, Yang Y, Zhang H (2018) Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage. Thorax 73(4):308–310. https://doi.org/10.1136/thoraxjnl-2017-211135 CrossRefPubMed

100.

Tang Y, El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Rosas IO, Moss J, Priolo C, Henske EP (2019) Metabolic changes in patients with lymphangioleiomyomatosis treated with sirolimus and hydroxychloroquine. Chest. https://doi.org/10.1016/j.chest.2019.05.038

101.

Yoon HY, Hwang JJ, Kim DS, Song JW (2018) Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis. Orphanet J Rare Dis 13(1):204CrossRef

102.

Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol 29(9):1918–1925CrossRef

103.

Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR (2018) Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open 3(2):e000291CrossRef

104.

Jones AT, Yang J, Narov K, Henske EP, Sampson JR, Shen MH (2019) Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2(+/-) mice. Neoplasia 21(8):731–739CrossRef

105.

Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA (2019) SWOG S1400B (NCT02785913), a Phase II study of GDC-0032 (Taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (Lung-MAP Sub-Study). J Thorac Oncol 14(10):1839–1846. https://doi.org/10.1016/j.jtho.2019.05.029 CrossRefPubMed

106.

Adjei AA, Bennouna J, Leighl NB, Felip E, Cortinovis DL, Alt J, Schaefer ES, Thomas M, Chouaid C, Morabito A, De Castro J, Grossi F, Paz-Ares L, De Pas TM, Maier J, Chakravartty A, Chol M, Aimone P, Planchard D (2016) Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies. Journal of Clinical Oncology 34 (15_suppl):e20522-e20522. https://doi.org/10.1200/JCO.2016.34.15_suppl.e20522

107.

Vansteenkiste JF, Canon JL, De Braud F, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC (2015) Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study. J Thorac Oncol 10(9):1319–1327CrossRef

108.

David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10(20):6865–6871CrossRef

109.

Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, Kim YH, Lee SY, Lee CT, Jheon S, Chung JH (2012) Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 460(6):601–609. https://doi.org/10.1007/s00428-012-1239-6 CrossRefPubMed

110.

Yip PY, Cooper WA, Kohonen-Corish MR, Lin BP, McCaughan BC, Boyer MJ, Kench JG, Horvath LG (2014) Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer. J Clin Pathol 67(4):333–340. https://doi.org/10.1136/jclinpath-2013-201870 CrossRefPubMed

111.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R (2017) Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun 8(1):410. https://doi.org/10.1038/s41467-017-00450-6 CrossRefPubMedPubMedCentral

112.

Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien ME, Popat S, Bhosle J, Banerji U (2014) AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung Cancer 85(2):141–146. https://doi.org/10.1016/j.lungcan.2014.05.008 CrossRefPubMed

113.

Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR (2015) Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who Previously progressed on erlotinib. Clin Cancer Res 21(19):4321–4326. https://doi.org/10.1158/1078-0432.CCR-14-3281 CrossRefPubMedPubMedCentral

114.

Owonikoko TK, Khuri FR (2013) Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/EdBook_AM.2013.33.e395

115.

Gonzalez-Angulo AM, Blumenschein GR Jr (2013) Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313–320. https://doi.org/10.1016/j.ctrv.2012.11.002 CrossRefPubMed

116.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022–8030. https://doi.org/10.1158/0008-5472.Can-08-1385 CrossRefPubMed

117.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18(1):26. https://doi.org/10.1186/s12943-019-0954-x CrossRefPubMedPubMedCentral

118.

Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC (2016) Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Oncotarget 7(9):10547–10556. https://doi.org/10.18632/oncotarget.7234 CrossRefPubMedPubMedCentral

119.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS (2017) AKT inhibition in solid tumors with AKT1 mutations. Journal of Clinical Oncology 35(20):2251–2259. https://doi.org/10.1200/JCO.2017.73.0143 CrossRefPubMedPubMedCentral

120.

Gkountakos A, Pilotto S, Simbolo M, Vicentini C, Mafficini A, del Curatolo A, Scarpa A, Tortora G, Corbo V, Bria E (2018) Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: a comprehensive preclinical analysis in squamous cell lung cancer. Ann Oncol 29(suppl_8):viii649–viii669. https://doi.org/10.1093/annonc/mdy303.049

121.

O'Reilly T, McSheehy PM (2010) Biomarker development for the clinical activity of the mtor inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 3(2):65–79. https://doi.org/10.1593/tlo.09277 CrossRefPubMedPubMedCentral

122.

Kwei KA, Baker JB, Pelham RJ (2012) Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS One 7(9):e46518. https://doi.org/10.1371/journal.pone.0046518 CrossRefPubMedPubMedCentral

123.

Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, Savage H, Guan Z, Hong R, Kassees R, Lee LB, Risom T, Gross S, Liederer BM, Koeppen H, Skelton NJ, Wallin JJ, Belvin M, Punnoose E, Friedman LS, Lin K (2013) Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 19(7):1760–1772. https://doi.org/10.1158/1078-0432.Ccr-12-3072 CrossRefPubMed

Title: mTOR in Lung Neoplasms
Authors: Ildiko Krencz
Anna Sebestyen
Andras Khoor
Publication date: 01-01-2020
Publisher: Springer Netherlands
Keywords: NSCLC
NSCLC
SCLC
SCLC
mTOR-Inhibitors
Published in: Pathology & Oncology Research / Issue 1/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-020-00796-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis

Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis

Gene Expression Profiles in Chemokine (C-C Motif) Ligand 21-Overexpressing Pancreatic Cancer Cells

Targeted Mutational Profiling and a Powerful Risk Score as Additional Tools for the Diagnosis of Papillary Thyroid Cancer

Inactivating Frameshift Mutations of HACD4 and TCP10L Tumor Suppressor Genes in Colorectal and Gastric Cancers

Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer